Amyloidosis - 258 Studies Found
| Completed |
: Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation : Transthyretin Cardiac Amyloidosis : 2025-08-13 : Tafamidis 61 mg by mouth daily for 12 months |
| Completed |
: Ultrasound Therapy In Cardiac Amyloidosis : Amyloidosis Cardiac : 2025-08-13 : Use of high mechanical index ultrasound therapy with intravenous Definity contrast infusion |
| NOT_YET_RECRUITING |
: Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis : Light Chain (AL) Amyloidosis : 2025-08-13 : NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antige |
| COMPLETED |
: This Study Will Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis : Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype : 2025-08-13 : 80 or 61 milligrams (mg) |
| Completed |
: The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis. : Transthyretin Amyloidosis : 2025-08-13 : 99mTc-DPD scintigraphy |
| Completed |
: Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis : Amyloidosis; Systemic : 2025-08-13 : AT-02 via IV infusion |
| COMPLETED |
: Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR : Transthyretin Amyloidosis : 2025-08-13 : Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging |
| COMPLETED |
: A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers : Transthyretin-mediated Amyloidosis : 2025-08-13 : an autoinjector with 0.8 mL deliverable volume (at 56 mg/mL concentration) will be provided, total dose is 45 mg. |